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ABSTRACT: A bioinspired glucose-responsive insulin delivery system for self-
regulation of blood glucose levels is desirable for improving health and quality of
life outcomes for patients with type 1 and advanced type 2 diabetes. Here we
describe a painless core−shell microneedle array patch consisting of degradable
cross-linked gel for smart insulin delivery with rapid responsiveness and excellent
biocompatibility. This gel-based device can partially dissociate and subsequently
release insulin when triggered by hydrogen peroxide (H2O2) generated during the
oxidation of glucose by a glucose-specific enzyme covalently attached inside the
gel. Importantly, the H2O2-responsive microneedles are coated with a thin-layer
embedding H2O2-scavenging enzyme, thus mimicking the complementary
function of enzymes in peroxisomes to protect normal tissues from injury caused
by oxidative stress. Utilizing a chemically induced type 1 diabetic mouse model, we
demonstrated that this smart insulin patch with a bioresponsive core and
protective shell could effectively regulate the blood glucose levels within a normal range with improved biocompatibility.
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Diabetes mellitus, a chronic disease affecting 422 millionpeople worldwide in 2016, is characterized by a deficitof endogenously produced insulin and elevated blood
glucose levels (BGLs).1,2 In the absence of proper control,
chronically elevated BGLs can lead to limb amputation,
blindness, kidney failure, and cardiovascular disease.3 To
prevent these diabetic complications, patients with type 1 and
advanced type 2 diabetes use injected or infused insulin to
achieve normoglycemia.4 However, open-loop exogenous
insulin injection or infusion generally fails to reach targets
and carries the additional risk of hypoglycemia when insulin
doses exceed that needed; these hypoglycemic episodes can be
severe and even lethal.3 Therefore, there is an urgent need for a
bioinspired “artificial β-cell” system that can intelligently
“secrete” desirable amounts of insulin in response to elevated
BGLs while maintaining basal insulin release kinetics at
normoglycemia. To this end, closed-loop device-based systems
have been developed and integrate a patient-calibrated
continuous glucose-monitoring sensor and an external insulin
infusion pump.5 However, such systems remain challenging
regarding algorithm accuracy and sensor reliability.6 Meanwhile,
chemically engineered formulations or devices that can swell,
degrade, or dissociate in response to ambient elevated BGLs
have attracted increasing attention as an alternative solu-
tion.7−11 These systems typically employ one of three different
mechanisms of actions,12,13 based on glucose oxidase
(GOx),9,10,14−20 phenylboronic acid (PBA),21−26 and glucose
binding proteins (GBP), respectively.27−29 GOx catalyzes the
oxidation of D-glucose to D-gluconolactone, which can hydro-
lyze to gluconic acid and generate hydrogen peroxide in the
presence of oxygen:
+ + ⎯ →⎯⎯ +glucose O H O gluconic acid H O2 2
GOx
2 2
Accordingly, acidity-sensitive systems entrapping GOx can
create a local acidic environment in response to elevated
glucose levels to trigger the release of insulin. However, it is
highly challenging to rapidly switch the physiological pH in vivo
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to achieve fast response.15 We have previously developed a
hypoxia-sensitive formulation to achieve a fast response, based
on the enzymatic consumption of local oxygen level.14
However, this formulation is limited by the hydrogen peroxide
that remains in this system, raising concerns over long-term
biocompatibility.30 Moreover, the simultaneous release of GOx
with insulin has the potential to cause systemic toxicity.31
Moving forward, the next generation of smart insulin delivery
should be developed to prioritize rapid responsiveness, ease of
preparation and administration, and excellent biocompatibility.
Here, we report a core−shell microneedle (MN) array
patch32,33 consisting of degradable cross-linked poly(vinyl
alcohol) (PVA) gel for self-regulated insulin delivery with
rapid responsiveness to elevated BGLs. As shown in Figure 1a,
the core component of this device contains GOx that generates
H2O2 to stimulate the release of insulin, while the shell
component is embedded with catalase (CAT) that serves as an
active strainer to scavenge excessive H2O2, thus minimizing the
risk of inflammation caused by H2O2 (Figure S1). To achieve
H2O2-responsive insulin release, insulin is chemically modified
with 4-nitrophenyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl) benzyl carbonate (designated insulin-NBC, Figure 1b) and
subsequently anchored to the water-soluble PVA matrix.34 Of
note, to further facilitate transport of free insulin in the
polymeric matrix and promote responsiveness speed, PVA is
also gelated by an H2O2-labile linker: N
1-(4-boronobenzyl)-N3-
(4-boronophenyl)-N1,N1,N3,N3-tetramethylpropane-1,3-diami-
nium (TSPBA) (Figure 1c). Both insulin-NBC and TSPBA are
oxidized and hydrolyzed when exposed to locally elevated levels
of H2O2 generated by GOx at high glucose concentrations,
35,36
leading to the quick release of free insulin (Figure 1a). To limit
the potentially harmful release of GOx itself,31 GOx is
encapsulated into the acrylated nanogel (GOx-NG) to acquire
a large size10 and get immobilized with covalent linkage to PVA
methacrylate during radical polymerization, which forms a
partially uncleavable network of PVA to further prevent the
leakage of GOx-NG while maintaining ease of insulin release.
The shell component is designed to mimic the complementary
function in peroxisome37 where catalase nanogel (CAT-NG)10
is formed and embedded inside a cross-linked PVA layer
covering the surface of PVA-TSPBA MN core. Collectively, the
design of the core and shell components offers: (1) sufficient
catalysis with GOx to perform the glucose-responsive action in
the core and (2) efficient elimination of H2O2 to alleviate
inflammation affecting the surrounding tissues and mitigate
systemic toxicity. Additionally, the direct conjugation method
that is utilized to load insulin onto the MN scaffold enhances
both efficiency and capacity of the insulin-loading process.
Upon painless transcutaneous administration, this biorespon-
sive MN patch partially dissolves when exposed to high
interstitial fluid glucose concentration in the capillary net-
works,14 thereby releasing insulin for quick uptake through the
regional capillary vessels and lymph networks to subsequently
regulate BGLs.14
RESULTS AND DISCUSSION
TSPBA was synthesized using quaternization reaction of
N1,N1,N3,N3-tetramethylpropane-1,3-diamine in the presence
of excess 4-(bromomethyl)phenylboronic acid (Scheme S1).
The quaternary ammonium groups on TSPBA significantly
enhanced its water solubility (∼100 mg/mL), which facilitates
the gel formation with PVA aqueous solution without organic
solvents. Upon oxidation in the presence of 10 mM H2O2, 70%
of TSPBA released p-quinone methide (p-hydroxylmethylene-
phenol) and became tertiary amines in 1 h as demonstrated by
1H NMR (Figure S2).35 Insulin-NBC was prepared in the
presence of a slight excess of NBC in a mixed solvent
composed of DMSO and 10 mM NaHCO3 aqueous solution.
36
The product was purified using preparative scale high-
performance liquid chromatography (HPLC)22 and was
confirmed by molecular weight to be a conjugate of one
insulin modified by one NBC using MALDI-TOF mass
spectroscopy (Figure S3). Importantly, insulin-NBC had
much higher aqueous solubility (>100 mg/mL) at pH 7.4
than native insulin, which was critical to prepare MN gels with a
high loading capacity of insulin. The phenylboronic ester of
insulin-NBC can be hydrolyzed in an aqueous solution; this
reaction is facilitated in the presence of diols.36 The insulin-
Figure 1. Schematic representation of the glucose-responsive insulin delivery system using H2O2 responsive PVA-TSPBA gel. (a) Insulin is
triggered to release by a hyperglycemic state from the core matrix of the PVA-TSPBA MN patch, and the local inflammation can be greatly
reduced by the catalase embedded PVA-TSPBA shell. (b) Modification of insulin with NBC and the mechanism of H2O2-responsive release.
(c) Schematic of the H2O2-responsiveness mechanism of PVA-TSPBA gels.
NBC could then be conjugated to PVA chains via the kinetic
ester bond between the phenylboronic acid and the cis-1,3-diol
in PVA.38 Addition of TSPBA to this reaction solution led to a
rapid increase in the elastic (G′) modulus and formation of a
network between the PVA chains in 60 s (Figure S4).39 The
gelation of PVA by TSPBA is critical for maintaining the
integrity of the shell structure, which is composed of water-
sensitive materials, and specifically prevents its dissolution to
aqueous solution when preparing the core.
The H2O2-sensitive insulin release was evaluated in the
presence of 10 mM H2O2 in PBS at pH 7.4. Insulin was
released from a formed gel with the addition of H2O2 at a
steady rate, and more than half of insulin was released within 2
h (Figure 2a). Although the esters between phenylboronic acids
and diols are generally unstable in acidic solution,40 the gel
formed between PVA and phenylboronic acid is stable in the
acidic environment.38 At pH 3.5, the gel showed high stability,
and insulin was released at a rather slow rate as compared to
that at pH 7.4.
Next, the release rate of insulin was assessed in the presence
of GOx in PBS at initial pH 7.4 at three different glucose
concentrations, including a typical hyperglycemic level (400
mg/dL), a normoglycemic level (100 mg/dL), and a control
level (0 mg/dL). The H2O2 generation rate was measured using
a fluorometric hydrogen peroxide assay kit.41 At the hyper-
glycemic glucose concentration of 400 mg/dL, H2O2
generation was efficient and reached as high as 6 mM within
60 min (Figure 2b). Compared to the hyperglycemic solution,
H2O2 was generated at a much slower rate in the
normoglycemic solution of 100 mg/dL glucose. The insulin
release corresponded to the H2O2 release such that the insulin
release rate was dramatically promoted under a glucose
concentration of 400 mg/dL compared to that of 100 mg/
dL, whereas negligible insulin release was observed when the
gel was incubated in the control solution (Figure 2c),
consistent with the morphology change of gels (Figure 2d).
Moreover, the release rate of insulin from PVA-TSPBA gels
was steadily enhanced when gradually increasing the glucose
concentrations of the tested solutions from normoglycemic to
hyperglycemic conditions, where a maximum of a 15-fold
difference in insulin release rate was achieved in 2 h when the
glucose concentration was increased from 100 to 400 mg/dL
(Figure 2e). The limited release of insulin at normoglycemia is
a significant safety feature for the in vivo application.
Additionally, a pulsatile kinetic release profile of insulin was
monitored for several cycles by alternately varying glucose
concentrations between normoglycemic and hyperglycemic
conditions, and the pulsatile release profile of insulin was
achieved when the gels were alternately exposed to the normal
and hyperglycemic levels (Figure 2f). In sum, these findings
suggest that the dissociation of cross-linked gels only takes
place under hyperglycemic conditions, and the PVA-TSPBA
gels release insulin in a glucose concentration-dependent
behavior. Finally, the far-UV circular dichroism (CD) spectra
of the native and released insulin from gels (1 mg/mL) were
similar, suggesting that released insulin retains α-helical
secondary structure and bioactivity (Figure S5).
To fabricate the core−shell MN gel, PVA-TSPBA gels were
integrated into MN array patch using a micromolding
approach.14 We developed a “solution-gelation” method to
conveniently load the cross-linked gel into MNs and form a
core−shell structure. Briefly, diluted aqueous solutions of PVA,
TSPBA, and CAT-NG (Figure S6) with low viscosity were
prepared, combined, and deposited in a silicone mold. The
mixed solution was kept in the mold under vacuum for 30 min
and then centrifuged at 500 rpm for 1 h to form a “shell” on the
mold. Another round of diluted aqueous solutions of PVA,
insulin-NBC, TSPBA, and GOx-NG (Figure S7) were loaded
into the mold, and this procedure was repeated for several
times until a predetermined amount of insulin-loaded gel was
achieved. During this process, methacrylated PVA and radical
initiator were added to the native PVA aqueous solution to
Figure 2. In vitro glucose-responsive insulin release from PVA-TSPBA gels. (a) Insulin release from PVA-TSPBA gels in PBS with 10 mM
H2O2 at pH 7.4 and 3.5. (b) Glucose concentration-dependent generation of H2O2 in PBS 7.4 in the presence of GOx (0.2 mg/mL). (c)
Glucose concentration-dependent insulin release from gels in PBS 7.4 in the presence of GOx (0.2 mg/mL). The glucose concentration was
set as 0, 100, and 400 mg/dL. (d) the glucose concentration-dependent morphology changes of gels in PBS 7.4 with GOx (0.2 mg/mL). (e)
Self-regulated insulin release profile as a function of glucose concentration. (f) Pulsatile insulin release profile as a function of glucose
concentrations over time. Data points represent mean ± SD (n = 3). Error bars indicate SD.
form a partially nondegradable network. Finally, hyaluronic acid
(HA) aqueous solution was cast and dried under vacuum to
provide a base for the mechanical support.14 The resulting
device was arranged in a 20 × 20 MN array on a 12 × 12 mm2
patch. The needle had a conical shape with a base diameter of
300 μm, 5 μm at the tip, and a height of 600 μm (Figure 3a).
The structure of MNs was confirmed by SEM and fluorescence
microscopy (Figure 3b−c). The mechanical strength of MN
was determined as 2 N/needle (Figure 3d), which sufficiently
allows for skin insertion without breaking.42,43 To validate the
feasibility of coating a CAT layer on MN arrays, a hollow MN
array patch constructed by rhodamine B labeled CAT-NG-
loaded PVA-TSPBA gel shell was prepared. These hollow MNs
showed a complete shell structure in a bottom view, side view,
or overhead view (Figure 3e; Figure S8). In addition, we found
that the integrity of this CAT-NG-loaded shell was not affected
when preparing the core part (Figure 3f). Collectively, these
results demonstrated the feasibility of preparing a core−shell
MN array, with a core loaded with insulin and GOx-NG, in
addition to a shell embedded with CAT-NG. The methacry-
lated PVA formed gel was shown to selectively release insulin
over GOx-NG (Figure 3g; Figure S9). Release of GOx-NG was
likely prevented due to its much larger size (∼12 nm) than
insulin, thereby reducing the potential local and systemic
toxicity of GOx.31
The in vivo performance of the core−shell MN array patches
was evaluated in a mouse model of type 1 diabetes induced by
streptozotocin (STZ). The mice were divided into six groups:
(1) treatment with CAT-NG shelled MN array patch of GOx-
NG and insulin-NBC-loaded gels (MN-CAT); (2) treatment
with subcutaneous injection of human recombinant insulin; (3)
treatment with MN array patch of GOx-NG and insulin-NBC-
loaded gels (MN-Gel(G+I)) without a shell; (4) treatment with
MN array patch only loaded with blank gel (MN-Gel); (5)
treatment with MN array patch of insulin-NBC-loaded gels
(MN-Gel(I)); and (6) treatment with MN array patch of GOx-
NG, insulin-NBC, and CAT-NG-loaded gels (MN-Gel(G+C
+I)). The insulin dosage was set at 50 mg/kg for all MN-based
insulin treatments. Staining by trypan blue indicated successful
penetration of MNs in the excised skin (Figure 4a−b).44 In
addition, the temporal microchannels on the skin caused by
MNs recovered quickly within 2 h post-treatment (Figure S10).
BGLs of the mice were monitored over time following
administration. A rapid decrease of BGLs of mice treated by
MN-Gel(G+I) (Figure S11) and MN-CAT (Figure 4c) was
observed in 30 min post-administration, and no significant
difference has been observed between these two groups,
indicating that CAT shell does not affect the local
concentration of H2O2 in the MN core. The BGLs then slowly
decreased to around 100 mg/dL and maintained near 200 mg/
dL for almost 6 h, much longer than subcutaneously injected
insulin (Figure 4c). This was attributed to the quick local
generation of H2O2 through the oxidation of glucose in the
presence of GOx as well as the high sensitivity of gel to H2O2.
In contrast, no obvious BGLs reduction was observed for the
mice treated with MN-Gel(I), MN-Gel (G+C+I), and MN-Gel.
These results were consistent to that observed in diabetic mice
subcutaneously injected with PVA-TSPBA gel with or without
GOx (Figure S12). Taken together, these observations
confirmed the essential role of H2O2 in releasing insulin as
well as the high stability of insulin-NBC in PVA-TSPBA gel in
the physiological environment. In vitro, CAT can preferentially
decompose H2O2 efficiently at normoglycemia (100 mg/dL)
(Figure S13). However, the capability of MN-Gel(G+C+I) to
reduce BGLs was significantly inhibited because limited insulin
can be released from MN due to the in situ exhaustion of H2O2
in the presence of CAT in the MN core even under a
hyperglycemic condition (Figure 4c), suggesting the necessity
Figure 3. Characterization of MN array patch of PVA-TSPBA. (a) Representative fluorescence microscopy images of insulin-loaded MN arrays
with HA base. Rhodamine B labeled insulin was loaded in PVA-TSPBA gel at the top of MNs (red), while the HA base (green, labeled by
FITC-insulin) was mainly located at the bottom. (b) Representative fluorescence image of MN array patch loaded with insulin-FITC. Scale
bars, 500 μm. (c) Representative scanning electron microscopy image of MN patch. Scale bar, 300 μm. (d) Mechanical strength of MNs. (e)
Representative images of a bottom view of hollow CAT-loaded MNs. These images were obtained using confocal laser scanning microscopy,
and the intervals at z-direction were set as 100 μm. Scale bar, 300 μm. (f) Representative images of a cross-section of core−shell MN using
cryosection: rhodamine B labeled CAT shell (red), FITC labeled insulin (green), and their overlap. The shell was 25 μm thick as analyzed
using software ImageJ. Scale bar, 300 μm. (g) The time-dependent release of GOx or GOx-NG from PVA methacrylate gel.
to separate CAT in a shell part to establish a robust level of
H2O2 in the core part locally. Additionally, the plasma human
insulin levels in mice treated with MN-CAT and MN-Gel(G+I)
were significantly higher than those treated with MN-Gel(I)
(Figure S14).
Intraperitoneal glucose tolerance tests (IPGTTs) were
further carried out 1 h post-administration of MNs or insulin.
A spike in BGLs was observed for all groups after the IPGTT
(Figure 4d). However, only healthy mice and MN-CAT could
restore blood glucose levels to a normoglycemic level within a
short period, and the mice treated with MN-CAT showed
significantly enhanced glucose tolerance to the glucose
challenge (Figure 4e). In order to assess the risk of
hypoglycemia associated with treatment by MN-CAT, the
BGLs of healthy mice treated with MN array patch were
observed. The BGLs of mice treated with insulin showed a
remarkable decrease, while the BGLs of mice treated with MN-
CAT showed only a slight decrease, consistent with the slow
release of insulin from gels under normoglycemic state (Figure
4f). Additionally, the MN-CAT treated group showed
significantly lower hypoglycemia index than insulin (Figure
4g), suggesting that the MN-CAT is safe for clinical application.
Furthermore, a 40-hour-long consecutive MN administration
was performed to evaluate the in vivo glucose control capability
of MN (Figure 4h). During this time, BGLs were maintained in
a narrow range between 100 and 250 mg/dL, and critically, no
hypoglycemia was recorded.
The reaction between the phenylboronic acid and H2O2
alleviates the harm of generated H2O2 to surrounding tissues.
However, any excessive unreacted H2O2 still carries the
potential to be harmful. Compared to the skin treated with
MN-Gel (Figure 5a), apparent inflammation was observed for
mice treated with MN-Gel(G+I). A similar phenomenon was
observed for skins treated with directly subcutaneously injected
gel (Figure S15). In sharp contrast, almost no visible
inflammation was observed on skins of mice treated with
MN-CAT and MN-Gel(G+C+I) (Figure 5a). These findings
were reinforced in hematoxylin and eosin (H&E) staining
results. Compared with skin treated with MN-Gel, skin samples
treated with MN-Gel(G+I) showed obvious neutrophil
infiltration, indicating a pathophysiological response and tissue
damage induced by the generated H2O2.
45 However,
substantially reduced neutrophil infiltration was observed in
the skin of mice treated with MN-Gel(G+C+I) and MN-CAT.
The epidermal thickness and skin thickness for mice treated
with both MN-CAT and MN-Gel(G+C+I) were comparable to
that of skin treated with blank MN but significantly thinner
than they were for mice treated with MN-Gel(G+I) (Figure
5b).46 Moreover, the skin tissue stained with the in situ terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay clearly demonstrated the cell apoptosis in
Figure 4. In vivo evaluation of MN array patches for type 1 diabetes treatment. (a) Mice treated with a MN array patch (left), and the skin
inserted by MN array patch was excised and stained using trypan blue (right). Scale bar, 600 μm. (b) Representative images of core−shell
MNs inserted into skins: the shell embedding rhodamine B labeled CAT (red), the core labeled by insulin-FITC (green), and their overlap.
Scale bar, 100 μm. (c) Blood glucose levels of type 1 diabetic mice treated with different kinds of MN array patches. (d) In vivo glucose
tolerance test toward diabetic mice at 1 h post-treatment of MN-CAT or subcutaneously injected with insulin. Healthy mice were used as the
control. (e) Responsiveness was calculated based on the area under the curve (AUC) in 120 min, with the baseline set at the 0 min blood
glucose reading. (f) Blood glucose levels change in healthy mice treated with MN array patch or subcutaneously injected insulin. The
treatment was given at 0 min. (g) Quantification of the hypoglycemia index, identified as the difference between the initial and nadir blood
glucose readings divided by the time at which nadir was reached. (h) Blood glucose levels change in diabetic mice treated with multiple MN-
array patches. The administration of MN-CAT was indicated by blue arrows. Each time, there were two MNs on mice except the first one, and
the last two MNs were removed as indicated by red arrows. Student’s t test: **P < 0.01. Data points represent mean ± SD (n = 5). Error bars
indicate SD.
the skin sample treated with MN-Gel(G+I), whereas negligible
cell death was observed in the skin tissue treated with CAT-
loaded or coated MNs (Figure 5c).
CONCLUSIONS
In summary, we demonstrated a core−shell gelated MN-array
patch for glucose-responsive smart insulin delivery. The MN-
Gels were prepared via a “solution-gelation” method involving
layer-by-layer deposition of the diluted solution. In vitro
experiments showed that this cross-linked gel could rapidly
release insulin when triggered by GOx-generated H2O2 under
hyperglycemic conditions. Elevated local levels of H2O2
promote detachment of insulin from the gel matrix and
degradation of the matrix itself, which contributes to the
efficient glucose responsiveness. In vivo experiments indicated
that the MN-CAT was highly effective in regulating BGLs and
maintaining normoglycemia while avoiding the critical risk of
hypoglycemia. Importantly, utilization of CAT coating shows
significant promise to eliminate the inflammation caused by the
generated H2O2. This bioresponsive core−shell MN array
patch offers a platform technique for transdermal drug delivery
in a physiological factor-controlled manner and enhanced
biocompatibility.47−50
METHODS
H2O2 Generation Rate Assay in Glucose Solution in the
Presence of GOx. The H2O2 concentration was determined using a
fluorometric hydrogen peroxide assay kit according to the
manufacturer’s protocol (Sigma-Aldrich). Glucose solutions (100 or
400 mg/dL) containing GOx (0.2 mg/mL) were incubated at 37 °C.
Samples (10 μL each tube) were withdrawn and diluted at timed
intervals, and the fluorescence intensity was detected.
Preparation of Insulin-NBC-Loaded PVA-TSPBA Gel. PVA-
TSPBA gel was prepared by mixing PVA and TSPBA. PVA (10 wt %
in H2O, 100 μL) and insulin-NBC (10 wt % in H2O, 30 μL) were
mixed first, followed by the addition of TSPBA (10 wt % in H2O, 30
μL) to fabricate a tough gel. During the in vitro insulin release
experiment, this gel was cut into pieces and incubated under different
conditions.
In Vitro Insulin Release from PVA-TSPBA Gels. Insulin-NBC-
loaded PVA-TSPBA gels were equally divided into centrifuge tubes
containing 1 mL 10 mM PBS at pH 7.4. Various amounts of glucose
(0, 100, or 400 mg/dL final concentration) and GOx (0.2 mg/mL)
were added to the solution. At predetermined time intervals, solution
(10 μL each tube) was withdrawn and stained with Coomassie blue
(200 μL), and the absorbance at 595 nm was detected on an Infinite
200 PRO multimode plate reader (Tecan Group Ltd.). The insulin
concentration was calibrated by a standard curve.
Fabrication of Microneedle Array Patch (with MN-CAT as an
Example). MNs used in this study were prepared via five silicone
molds purchased from Blueacre Technology Ltd. Each MN had a
round base of 300 μm in diameter, which tapers over a height of 600
μm to a tip radius of around 5 μm. The MNs were arranged in a 20 ×
20 array with 600 μm tip−tip spacing. First, diluted aqueous solutions
of PVA (3.5 wt % in H2O, 450 μL), TSPBA (3.5 wt % in H2O, 150
μL), and CAT-NG (1 mg in 400 μL H2O) were prepared and mixed.
After deposition in a silicone mold, the solution was kept under
reduced vacuum for 30 min and then transferred to a Hettich
Universal 32R centrifuge for 20 min at 500 rpm to compact gel
solution into MN cavities to form a membrane on the mold. Then,
diluted aqueous solutions of PVA, methacrylated PVA, TSPBA, GOx-
NG, and photoinitiator (Irgacure 2959; 5 wt %/vol) were loaded into
mold, and this procedure was repeated for several times until
predetermined amounts of insulin-NBC gel were loaded. Finally, 2 mL
HA (4 wt % in H2O) was filled in each micromold surrounded by
silver adhesive tape and dried under vacuum for 2 days. After the
desiccation, the MN array patches were separated from the silicone
molds carefully and exposed to UV irradiation (wavelength of 365 nm)
for a short period for cross-linking. The morphology of the MNs was
characterized using an FEI Verios 460L field-emission scanning
electron microscope.
Figure 5. In vivo biocompatibility studies of MN-CAT arrays for diabetes treatment. (a) Representative images of skins at the treated site of
mice and their corresponding H&E staining results. Mice were treated with MN-Gel, MN-Gel(G+I), MN-Gel(G+C+I), and MN-CAT. Scale
bars, 1 cm or 300 μm for mice skin images and H&E staining, respectively. (b) Statistical analysis of the thickness of epidermis and skins
treated by MNs. The epidermis and skin treated by MN-CAT showed significantly less swelling than that treated with MN-Gel(G+I) (**P <
0.01). Data points represent mean ± SD (n = 3). Error bars indicate SD. (c) Immunohistologic staining with TUNEL assay (green) and
Hoechst (blue) of skins treated with MN-Gel(G+I), MN-Gel(G+C+I) and MN-CAT. Scale bars, 150 μm.
In Vivo Studies Using Streptozotocin-Induced Diabetic Mice.
The in vivo efficacy of both MN-array patches and gels for diabetes
treatment was evaluated on streptozotocin-induced adult diabetic mice
(male C57B6, age 8 wk; Jackson Laboratory). The animal study
protocol was approved by the Institutional Animal Care and Use
Committee at North Carolina State University and the University of
North Carolina at Chapel Hill. MN array patch was pressed firmly for
the first 5 s, during which the shape and mechanical strength of MN
were maintained for easy penetration through the epidermis, and
pressed softly for additional 2 min to make MN absorb the liquid. The
plasma glucose was measured from tail vein blood samples (∼3 μL) of
mice using the Clarity GL2Plus glucose meter (Clarity Diagnostics).
Mouse glucose levels were monitored for 2 days before drug
administration. Five mice for each group were selected to be treated
using MN or native insulin. The glucose level of each mouse was
monitored until stabilization. For mice treated with insulin-NBC-
loaded gels, PVA (10 wt % in H2O), insulin-NBC (50 μg in 10 μL
H2O), GOx-NG (3 μg in 5 μL H2O), and TSPBA (10 wt % in H2O)
were consecutively injected subcutaneously to form the gel in situ.
Statistical Analysis. Differences in blood glucose levels between
the treated groups and controlled groups were determined by unpaired
Student’s t-test. The results were considered statistically significant if
the two-tailed P-values were <0.05. The statistical approach remained
consistent throughout all analyses.
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